Articles tagged with: Ricolinostat

Press Releases»

[ by | Dec 7, 2015 10:00 am | Comments Off ]

Interim Results from Phase 1b/2 ACE-MM-102 and Phase 1a/1b ACE-MM-200 Studies to be Presented at the 57th Annual Meeting of the American Society of Hematology

Boston (Press Release) Acetylon Pharma­ceu­ticals, Inc., the leader in the devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes, today announced that it will present clin­i­cal data demonstrating promising tolerability and over­all response rates from a Phase 1b/2 study of a selective HDAC6 inhibitor, ricolinostat (ACY-1215), in com­bi­na­tion with poma­lido­mide (Pomalyst®, Celgene) and dexa­meth­a­sone for the treat­ment of re­lapsed-and-refractory multiple myeloma (ACE-MM-102 study). These data …

Read the full story »

News, Opinion»

[ by | Jan 30, 2015 3:07 pm | 4 Comments ]
The Myeloma Quiz – January 2015

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a hap­pen­ing time for the mul­ti­ple myeloma com­munity. The short span of time witnessed the pub­li­ca­tion of up­dated criteria for the diag­nosis of mul­ti­ple myeloma from the Inter­na­tional Myeloma Work­ing Group (IMWG). In addi­tion, the 56th annual meeting of the American Society of He­ma­tol­ogy (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it is again …

Read the full story »

News»

[ by and | Dec 11, 2013 6:20 pm | Comments Off ]
ASH 2013 Multiple Myeloma Update - Day Three: Afternoon Oral Sessions

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and refractory, and older patients.

This ASH update highlights most of the oral …

Read the full story »

News»

[ by | Dec 9, 2013 1:13 pm | 2 Comments ]
ASH 2013 Multiple Myeloma Update - Day Two

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.

The myeloma study included in this session was …

Read the full story »

News»

[ by | Nov 18, 2013 10:22 pm | Comments Off ]
ASH 2013 Preview: Treatments In Early-Phase Clinical Development For Multiple Myeloma

This article is the second in The Beacon’s ‘preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available; these abstracts contain pre­lim­i­nary data, and updated data will be presented at the meet­ing.

The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.

The first preview, which was published last …

Read the full story »

News»

[ by and | May 24, 2013 4:23 pm | 8 Comments ]
The Future Of Treatment For Multiple Myeloma

In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Read the full story »

News»

[ by | Dec 12, 2012 2:57 pm | Comments Off ]
ASH 2012 Multiple Myeloma Update – Day Three: Poster Sessions

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.

It also was the busiest day of the meeting in regard to myeloma-related research.

The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall.  More than a hundred of the posters reported on the results of myeloma-related research.

Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development.  They may involve laboratory research, clinical …

Read the full story »